Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
NRG Oncology
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
University of Iowa
Alliance for Clinical Trials in Oncology
Rutgers, The State University of New Jersey
University of Washington
City of Hope Medical Center
NRG Oncology
M.D. Anderson Cancer Center
The Cleveland Clinic
University of Texas Southwestern Medical Center
NRG Oncology
Menoufia University
Center Eugene Marquis
Albert Einstein College of Medicine
EMD Serono
Laibin People's Hospital
National Cancer Institute (NCI)
RTOG Foundation, Inc.
Shanghai Chest Hospital
ChineseAMS
Jonsson Comprehensive Cancer Center
NYU Langone Health
National Cancer Institute (NCI)
University of Kentucky
M.D. Anderson Cancer Center
Guizhou Medical University
M.D. Anderson Cancer Center
Hunan Province Tumor Hospital
AHS Cancer Control Alberta
AHS Cancer Control Alberta
AHS Cancer Control Alberta
Fudan University
AZ-VUB